Ann Surg Treat Res.  2018 Nov;95(5):240-248. 10.4174/astr.2018.95.5.240.

ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line

• Hwang E
• Hwang SH
• Kim J
• Park JH
• Oh S
• Kim YA
• Hwang KT

• KMID: 2422933
• DOI: http://doi.org/10.4174/astr.2018.95.5.240

Abstract

PURPOSE
This study aimed to validate the synergistic effect of ABT-737 on docetaxel using MDA-MB-231, a triple negative breast cancer (TNBC) cell line overexpressing B-cell lymphoma-2 (Bcl-2).
METHODS
Western blot analysis was performed to assess expression levels of Bcl-2 family proteins and caspase-related molecules. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell cycle distribution was determined by flow cytometry analysis. Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (z-VAD-fmk) was used for pretreatment to assess the role of caspases.
RESULTS
Cell viability of MDA-MB-231 after combination treatment with ABT-737 and docetaxel was significantly lower than that after docetaxel or ABT-737 monotherapy based on MTT assay (both P < 0.001), with a combination index of 0.41. The proportion of sub-G1 population after combination treatment was significantly higher than that after docetaxel or ABT-737 monotherapy (P = 0.001, P = 0.003, respectively). Pretreatment with z-VAD-fmk completely restored cell viability of MDA-MB-231 from apoptotic cell death induced by combination therapy (P = 0.001). Although pro-caspase-8 or Bid did not show significant change in expression level, pro-casepase-9 showed significantly decreased expression after combination treatment. Cleaved caspase-3 showed increased expression while poly (ADP-ribose) polymerase cleavage was induced after combination treatment. However, hypoxia-inducible factor 1-alpha and aldehyde dehydrogenase 1 totally lost their expression after combination treatment.
CONCLUSION
Combination of ABT-737 with docetaxel elicits synergistic therapeutic effect on MDA-MB-231, a TNBC cell line overexpressing Bcl-2, mainly by activating the intrinsic pathway of apoptosis. Therefore, adjunct of ABT-737 to docetaxel might be a new therapeutic option to overcome docetaxel resistance of TNBCs overexpressing Bcl-2.

Keyword

ABT-737; Bcl-2; Docetaxel; Drug resistance; Triple negative breast neoplasms

MeSH Terms

Aldehyde Dehydrogenase
Apoptosis
B-Lymphocytes
Blotting, Western
Caspase 3
Caspase 8
Caspases
Cell Cycle
Cell Death
Cell Line*
Cell Survival
Drug Resistance
Flow Cytometry
Humans
Triple Negative Breast Neoplasms*
Aldehyde Dehydrogenase
Caspase 3
Caspase 8
Caspases

Figure

• 

  Fig. 1 Western blot analysis for ER, HER2, Bcl-2, Bcl-xL, and Bcl-w using 6 breast cancer cell lines and MTT assay using MDA-MB-231 and MDA-MB-468 after docetaxel or ABT-737 monotherapy. (A) After lysing harvested cells (1 × 106 cells per each cell line), equal amount of cell lysate extracted from 6 breast cancer cell lines using radioimmunoprecipitation assay buffer was subjected to Western blot analysis using specific antibodies. Signal intensity was normalized to that of β-actin as loading control. MTT assay was performed using MDA-MB-231 and MDA-MB-468 (5 × 103 cells per each cell line) after treatment with indicated concentration of docetaxel (B) and ABT-737 (C) for 72 hours. Cell viability (%) was expressed as a percentage of viable cell proportion for treated sample compared to that of untreated control. Values correspond to mean ± standard deviation of three independent experiments. Black squares indicate MDA-MB-231. White squares indicate MDA-MB-231. Statistical significance was assessed by unpaired Student t-test. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; Bcl-2, B-cell lymphoma-2; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NS, not significant. *P < 0.05. **P < 0.01. ****P < 0.0001.

• 

  Fig. 2 Cytotoxicity evaluation of docetaxel, ABT-737, and combination treatment using MDA-MB-231. (A) MDA-MB-231 cells (5 × 103) were treated with 10 nM docetaxel and/or 1 µM ABT-737 for 48 hours. Cellular morphology was observed by phase contrast microscopy (×100). White arrow indicates a suspended shrunk cell. Black arrow points to an attached surviving cell. (B) MDA-MB-231 cells (5 × 103) were treated with 20 nM docetaxel and/or 1 µM ABT-737 for 72 hours. Cell viability was assessed by MTT assay. Absorbance was measured at wavelength of 570 nm. Values correspond to mean ± standard deviation of three independent experiments. Statistical significance was assessed by unpaired Student t-test. NS, not significant. ***P < 0.001.

• 

  Fig. 3 Cell cycle analysis. (A) MDA-MB-231 cells (1 × 105) were treated with 10 nM docetaxel and/or 1 µM ABT-737 for indicated time periods and stained with 50 µg/mL of propidium iodide including 100 µg/mL of RNase A for 30 minutes at 37℃. Top, middle, and bottom rows were treated with ABT-737, docetaxel, and both drugs, respectively. Graphs depict data of flow cytometry results after treatment for 72 hours according to cell cycle (B) and treatment agents (C). Values correspond to mean ± standard deviation of 3 independent experiments. Statistical significance was assessed by unpaired Student t-test. NS, not significant. *P < 0.05. **P < 0.01.

• 

  Fig. 4 MTT assay and cell cycle analysis after docetaxel, ABT-737, and combination treatment using MDA-MB-231 with or without pretreatment of z-VAD-fmk. Twenty µM of z-VAD-fmk was pretreated for 1 hour before 10 nM docetaxel, 1 µM ABT-737, or combination treatment for 48 hours. (A) Cell viability after treatment was determined by MTT assay. Statistical significance was assessed by unpaired Student t-test. Values correspond to mean ± standard deviation of five independent experiments. (B) After treatment with docetaxel, ABT-737, or combination therapy, MDA-MB-231 cells (1 × 105) were stained with 50 µg/mL of propidium iodide with (bottom) or without (top) pretreatment of 20 µM z-VAD-fmk. (C) Percentage of each phase is shown as 100% stacked bar chart. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NS, not significant. **P < 0.01.

• 

  Fig. 5 Expression of apoptosis related molecules by Western blot. MDA-MB-231 cells were treated with 10 nM docetaxel, 1 µM ABT-737, or combination of the two drugs for 24 hours and 48 hours. After lysing harvested cells (1 × 106), 40 µg of protein from each cell lysate was loaded and blotted with specific antibodies, including caspase-8, caspase-9, cleaved caspase-3, Bid, and PARP antibodies. Expression levels of ALDH1 and HIF-1α were also tested under the same condition. β-actin was used as loading control. PARP, poly (ADP-ribose) polymerase; ALDH1, aldehyde dehydrogenase 1; HIF, hypoxia-inducible factor.

Reference

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363:1938–1948.

2. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010; 7:683–692.

3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429–4434.

4. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014; 15:49–63.

5. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984; 226:1097–1099.

6. Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, et al. Prognostic influence of BCL2 expression in breast cancer. Int J Cancer. 2012; 131:E1109–E1119.

7. Hwang KT, Han W, Kim J, Moon HG, Oh S, Song YS, et al. Prognostic influence of Bcl2 on molecular subtypes of breast cancer. J Breast Cancer. 2017; 20:54–64.

8. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010; 103:668–675.

9. Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008; 8:153.

10. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26:1275–1281.

11. Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer. 2009; 9:321–326.

12. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci U S A. 2012; 109:2766–2771.

13. Panayotopoulou EG, Muller AK, Borries M, Busch H, Hu G, Lev S. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells. Oncotarget. 2017; 8:45088–45104.

14. Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 2008; 68:7985–7994.

15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248–254.

16. Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007; 13:7191–7198.

17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27–55.

18. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015; 121:8–16.

19. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014; 20:782–790.

20. Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis. 2012; 3:e366.

21. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med. 2009; 361:1570–1583.

22. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116:205–219.

23. Ajabnoor GM, Crook T, Coley HM. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis. 2012; 3:e260.

24. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov. 2011; 10:221–237.

25. Ichim G, Tait SW. A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016; 16:539–548.

26. Herceg Z, Wang ZQ. Functions of poly (ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res. 2001; 477:97–110.

27. Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A. 2014; 111:E5429–E5438.

28. Chen CH, Ferreira JC, Gross ER, Mochly-Rosen D. Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev. 2014; 94:1–34.

29. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1:555–567.

30. Kida K, Ishikawa T, Yamada A, Shimada K, Narui K, Sugae S, et al. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype. Breast Cancer Res Treat. 2016; 156:261–269.